[1] [3] Tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 receptor agonist with similar clinical effects
1 Separating Myth from Fact Myth : Anyone can take GLP-1 weight-loss drugs
However, other relevant interactions, especially those regulating the pharmacological potency of DPDPE, such as those with R380, a key residue for peptide affinity and receptor activation at TM7, was absent (Griffith et al., 2022)
Some people also experience an impact on physical feelings of hunger and an impact on eating habits associated with reward (for example reduced pleasure in eating high-fat or sugary foods)
The changes in HDL-C, triglycerides, and total cholesterol were similar in STEP-1 and SELECT, and there remained a significant decrease in LDL-C even though patients started at a lower LDL-C level [33, 48]
S.KirkR